STAT

FDA cracks down on ‘vaginal rejuvenation’ devices, citing potential for serious harm

Products being marketed as “vaginal rejuvenation” devices have serious risks and don’t have adequate evidence to support their use for these purposes, the FDA says.
FDA Commissioner Scott Gottlieb

The Food and Drug Administration is cracking down on devices marketed for use in “vaginal rejuvenation.”

In a issued Monday, FDA Commissioner Scott Gottlieb said a growing number of manufacturers are marketing “vaginal rejuvenation”

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks